[go: up one dir, main page]

WO1996008274A3 - Conjugues d'un facteur de croissance semblable au facteur de croissance epidermique de type hbgf, et d'agents a cible definie - Google Patents

Conjugues d'un facteur de croissance semblable au facteur de croissance epidermique de type hbgf, et d'agents a cible definie Download PDF

Info

Publication number
WO1996008274A3
WO1996008274A3 PCT/US1995/012205 US9512205W WO9608274A3 WO 1996008274 A3 WO1996008274 A3 WO 1996008274A3 US 9512205 W US9512205 W US 9512205W WO 9608274 A3 WO9608274 A3 WO 9608274A3
Authority
WO
WIPO (PCT)
Prior art keywords
growth factor
conjugates
heparin
targeted
binding epidermal
Prior art date
Application number
PCT/US1995/012205
Other languages
English (en)
Other versions
WO1996008274A2 (fr
Inventor
Barbara A Sosnowski
Lois Ann Chandler
L L Houston
Michael P Nova
John R Mcdonald
Original Assignee
Prizm Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prizm Pharma Inc filed Critical Prizm Pharma Inc
Priority to AU37244/95A priority Critical patent/AU3724495A/en
Publication of WO1996008274A2 publication Critical patent/WO1996008274A2/fr
Publication of WO1996008274A3 publication Critical patent/WO1996008274A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0042—Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Conjugués d'un facteur de croissance (HBEGF) semblable au facteur de croissance épidermique de type HBGF, lié, directement ou par l'intermédiaire d'un agent de liaison, à un agent à cible définie. L'agent à cible définie est un agent cytotoxique tel qu'une protéine d'inactivation de ribosomes (RIP) et un acide nucléique anti-sens, ou bien un acide nucléique thérapeutique adapté pour être administré au niveau d'une cible définie. L'agent à cible définie est fixé au HBEGF, ou par l'intermédiaire d'un agent de liaison, au moyen d'une liaison chimique, ou bien le conjugué est préparé sous forme de chimère à l'aide des techniques de l'ADN recombiné. Les conjugués servent à diriger les agents cytotoxiques ou les nucléotides thérapeutiques vers des cellules portant des récepteurs du facteur de croissance épidermique, et trouvent une application notamment dans le traitement des tumeurs solides telles que les tumeurs du sein et de la vessie, et dans le traitement des affections impliquant une prolifération pathophysiologique des cellules musculaires lisses, par exemple la resténose.
PCT/US1995/012205 1994-09-13 1995-09-13 Conjugues d'un facteur de croissance semblable au facteur de croissance epidermique de type hbgf, et d'agents a cible definie WO1996008274A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU37244/95A AU3724495A (en) 1994-09-13 1995-09-13 Conjugates of heparin-binding epidermal growth factor-like growth factor with targeted agents

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30577194A 1994-09-13 1994-09-13
US08/305,771 1994-09-13
US44197995A 1995-05-16 1995-05-16
US08/441,979 1995-05-16

Publications (2)

Publication Number Publication Date
WO1996008274A2 WO1996008274A2 (fr) 1996-03-21
WO1996008274A3 true WO1996008274A3 (fr) 1996-04-04

Family

ID=26974775

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/012205 WO1996008274A2 (fr) 1994-09-13 1995-09-13 Conjugues d'un facteur de croissance semblable au facteur de croissance epidermique de type hbgf, et d'agents a cible definie

Country Status (2)

Country Link
AU (1) AU3724495A (fr)
WO (1) WO1996008274A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192736B2 (en) 1998-07-22 2007-03-20 Osprey Pharmaceuticals, Ltd. Nucleic acid molecules encoding cytotoxic conjugates that contain a chemokine receptor targeting agent

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037329A (en) * 1994-03-15 2000-03-14 Selective Genetics, Inc. Compositions containing nucleic acids and ligands for therapeutic treatment
CA2221269A1 (fr) * 1995-05-16 1996-11-21 Lois A. Chandler Compositions contenant des acides nucleiques et des ligands pour un traitement therapeutique
AU717277B2 (en) 1995-10-23 2000-03-23 Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
JP2002515784A (ja) * 1996-06-24 2002-05-28 セレクティブ ジェネティクス，インコーポレイテッド ヘパリン結合増殖因子結合体を含有するヘパリン処理医療用デバイス
US6838238B1 (en) * 1996-10-17 2005-01-04 Invitrogen Corporation Morphatides: novel shape and structure libraries
EP1075271A4 (fr) * 1998-04-17 2002-09-25 Univ Maryland Procede servant a traiter la cystite interstitielle au moyen d'un facteur de croissance semblable au facteur de croissance epidermique de recombinaison se fixant a heparine (hb-egf)
US7060433B1 (en) 1999-11-12 2006-06-13 Rigel Pharmaceuticals, Inc. Methods and compositions for screening using diphtheria toxin constructs
WO2001019989A2 (fr) * 1999-09-14 2001-03-22 Entremed, Inc. Procede de preparation et de purification d'une proteine d'endostatine¿tm?
WO2001034806A2 (fr) * 1999-11-12 2001-05-17 Rigel Pharmaceuticals, Inc. Procedes et compositions de depistage au moyen d'edifices de toxine de la diphterie
FR2805821B1 (fr) * 2000-03-01 2004-01-16 Diatos Sequences d'acides amines facilitant la penetration d'une substance d'interet a l'interieur des cellules et/ou des noyaux cellulaires
US8003595B2 (en) 2000-03-01 2011-08-23 Cellectis Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei
WO2004096254A2 (fr) * 2003-05-02 2004-11-11 Xpression Antibody Therapeutics, Inc. Compositions et procedes pour le traitement des tumeurs
WO2004096117A2 (fr) * 2003-05-02 2004-11-11 Xpression Antibody Therapeutics, Inc. Systemes d'administration d'acides nucleiques
AU2004265159B2 (en) 2003-08-14 2010-08-19 Cellectis Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei
WO2005033134A2 (fr) * 2003-09-30 2005-04-14 Regeneron Pharmaceuticals, Inc. Therapeutique et utilisations d'une proteine secretee
GB0718045D0 (en) 2007-09-14 2007-10-24 Peptcell Ltd Pharmaceutical compound
US9790264B2 (en) 2012-06-25 2017-10-17 The Brigham And Women's Hospital, Inc. Compounds and methods for modulating pharmacokinetics
CN104619727B (zh) * 2012-06-25 2019-04-05 布里格姆及妇女医院股份有限公司 靶向治疗
CN116390932A (zh) * 2020-06-24 2023-07-04 萨普雷米科技有限公司 用于在药品中使用的皂苷衍生物
US20240115726A1 (en) * 2020-06-24 2024-04-11 Sapreme Technologies B.V. Hydrazone-based saponin derivatives

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992006705A1 (fr) * 1990-10-16 1992-04-30 The Children's Medical Center Corporation Mitogene de liaison d'heparine presentant une homologie avec le facteur de croissance epidermique (egf)
WO1993025688A1 (fr) * 1992-06-16 1993-12-23 Whittier Institute For Diabetes And Endocrinology Production recombinee de proteines contenant de la saporine
WO1995003831A1 (fr) * 1993-08-02 1995-02-09 Prizm Pharmaceuticals, Inc. Preparations monogenes de conjugues cytotoxiques
WO1995024928A2 (fr) * 1994-03-15 1995-09-21 Prizm Pharmaceuticals, Inc. Facteurs de croissance des fibroplastes pour la therapie genique et le traitement de troubles du segment anterieur de l'oeil

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992006705A1 (fr) * 1990-10-16 1992-04-30 The Children's Medical Center Corporation Mitogene de liaison d'heparine presentant une homologie avec le facteur de croissance epidermique (egf)
WO1993025688A1 (fr) * 1992-06-16 1993-12-23 Whittier Institute For Diabetes And Endocrinology Production recombinee de proteines contenant de la saporine
WO1995003831A1 (fr) * 1993-08-02 1995-02-09 Prizm Pharmaceuticals, Inc. Preparations monogenes de conjugues cytotoxiques
WO1995024928A2 (fr) * 1994-03-15 1995-09-21 Prizm Pharmaceuticals, Inc. Facteurs de croissance des fibroplastes pour la therapie genique et le traitement de troubles du segment anterieur de l'oeil

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CHANDLER L. A. ET AL.: "CHARACTERIZATION OF MITOTOXINS CONTAING HEPARIN-BINDING EPIDERMAL GROWTH FACTOR-LIKE GROWTH FACTOR FUSED TO SAPORIN.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 36, no. 0, pages 425 *
CHEMICAL ABSTRACTS, vol. 121, no. 23, 5 December 1994, Columbus, Ohio, US; abstract no. 271455, MESRI, ENRIQUE A. ET AL: "The heparin-binding domain of heparin-binding EGF-like growth factor can target Pseudomonas exotoxin to kill cells exclusively through heparan sulfate proteoglycans" *
DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; *
E. A. MESRI ET AL.: "HEPARIN-BINDING TRANSFORMING GROWTH FACTOR ALPHA-PSEUDOMONAS EXOTOXIN A.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 7, 5 March 1993 (1993-03-05), MD US, pages 4853 - 4862, XP000578211 *
EIGHTY-SIXTH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, TORONTO,CANADA., 18 March 1995 (1995-03-18) - 22 March 1995 (1995-03-22) *
J. CELL SCI. (1994), 107(9), 2599-608 CODEN: JNCSAI;ISSN: 0021-9533 *
MICHAEL WESTBY ET AL.: "PREPARATION AND CHARACTERIZATION OF RECOMBINANT PRORICIN CONTAINING AN ALTERNATIVE PROTEASE-SENSITIVE LINKER SEQUENCE.", BIOCONJUGATE CHEMISTRY, vol. 3, WASHINGTON US, pages 375 - 381, XP002187830 *
S. A. THOMPSON ET AL.: "CHARACTERIZATION OF SEQUENCES WITHIN HEPARIN-BINDING EGF-LIKE GROWTH FACTOR THAT MEDIATE INTERACTION WITH HEPARIN.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 4, 28 January 1994 (1994-01-28), MD US, pages 2541 - 2549, XP000578210 *
ZHOU FEN ET AL.: "STRUCTURAL ORGANIZATION AND CHROMOSOMAL ASSIGNEMNET OF THE GEN ENCODING THE HUMAN HEPARIN-BINDING EPIDERMAL GROWTH FACTOR-LIKE GROWTH FACTOR/DIPHTHERIA TOXIN RECEPTOR.", BIOCHEMISTRY, vol. 32, EASTON, PA US, pages 7932 - 7938 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192736B2 (en) 1998-07-22 2007-03-20 Osprey Pharmaceuticals, Ltd. Nucleic acid molecules encoding cytotoxic conjugates that contain a chemokine receptor targeting agent

Also Published As

Publication number Publication date
WO1996008274A2 (fr) 1996-03-21
AU3724495A (en) 1996-03-29

Similar Documents

Publication Publication Date Title
WO1996008274A3 (fr) Conjugues d'un facteur de croissance semblable au facteur de croissance epidermique de type hbgf, et d'agents a cible definie
EP0259904B1 (fr) Thérapie anticancéreuse et médicaments cytotoxiques pour sa réalisation
US5502037A (en) Pro-cytotoxic drug conjugates for anticancer therapy
EP0699766A1 (fr) Protéines de fusion à base d'un anticorps thérapeutique avec facteur plaquettaire 4
US7807134B2 (en) Multidrug multiligand conjugates for targeted drug delivery
ZA958444B (en) Biological active proteins
EP0954340A4 (fr) Immunotherapie-cible associee contre le cancer
CA2053275A1 (fr) Substances conjuguees a base de facteur de croissance de fibroblaste
WO1988005077A1 (fr) Procede pour modifier le metabolisme de cellules eucaryotes lors de l'incorporation de sequences etrangeres d'acides nucleique s au moyen d'un vecteur d'internalisation
IL187388A0 (en) Use of a conjugate for preparing a composition for treating secondary tissue damage and other inflammatory conditions
WO1998051325A3 (fr) Peptides aleatoires se liant au recepteurs de transport du tractus gastrointestinal (git) et procedes y relatifs
ES2060947T3 (es) Un nuevo sistema de suministro de anticuerpos para modificadores de la respuesta biologica.
ES2193143T3 (es) Uso de inmunoconjugados para la diagnosis y/o terapia de tumores vascularizaos.
WO1999048536A3 (fr) Apport local d'agents therapeutiques a action prolongee
AU6721998A (en) Therapeutic use of the smr1 protein and active derivatives thereof
WO2002087497A3 (fr) Compositions therapeutiques conjuguees agent/ligand, leur methodes de synthese et leur utilisation
WO1997048804A3 (fr) Ligands de recepteurs de tie-2 (ligands-3 tie; ligands-4 tie) et leurs utilisations
Mickisch et al. Pseudomonas exotoxin conjugated to monoclonal antibody MRK16 specifically kills multidrug resistant cells in cultured renal carcinomas and in MDR-transgenic mice
US7368431B2 (en) Polypeptide, the conjugate thereof with doxorubicine and a pharmaceutical composition based thereon
WO2001036005A3 (fr) Liberation ciblee de fractions therapeutiques et de diagnostic
WO2001008708A3 (fr) Administration amelioree par l'intermediaire d'un recepteur du complexe enzyme inhibiteur de la serine protease
CN109152845B (zh) 含有在环内包含至少两个(-ch2-ch2-o-)单元的接头的缀合物和缀合试剂
Okamoto et al. Expression of fibroblast growth factor binding protein HBp17 in normal and tumor cells
Tsuruo et al. Enhanced cytocidal action of methotrexate by conjugation to concanavalin A
JP2005508875A5 (fr)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AU BB BG BR BY CA CN CZ EE FI GE HU IS JP KG KP KR KZ LK LR LT LV MD MG MN MX NO NZ PL RO RU SG SI SK TJ TM TT UA UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT.BUL.13/96 UNDER INID(54)"TITLE",REPLACE THE EXISTING TEXT BY"CONJUGATES OF HEPARIN-BINDING EPIDERMIAL GROWTH FACTOR-LIKE GROWTH FACTOR WITH TARGETED AGENTS"

AK Designated states

Kind code of ref document: A3

Designated state(s): AM AU BB BG BR BY CA CN CZ EE FI GE HU IS JP KG KP KR KZ LK LR LT LV MD MG MN MX NO NZ PL RO RU SG SI SK TJ TM TT UA UZ VN

Kind code of ref document: A3

Designated state(s): AM AU BB BG BR BY CA CN CZ EE FI GE HU IS JP KG KP KR KZ LK LR LT LV MD MG MN MX NO NZ PL RO RU SG SI SK TJ TM TT UA UZ KE

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)